144 related articles for article (PubMed ID: 38364975)
1. Efficacy and safety of the Spiration Valve System™ for the treatment of severe emphysema in patients with Alpha-1 antitrypsin deficiency (EMPROVE).
Hogarth DK; Delage A; Zgoda MA; Nsiah-Dosu S; Himes D; Reed MF
Respir Med; 2024 Apr; 224():107565. PubMed ID: 38364975
[TBL] [Abstract][Full Text] [Related]
2. Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE.
Criner GJ; Mallea JM; Abu-Hijleh M; Sachdeva A; Kalhan R; Hergott CA; Lazarus DR; Mularski RA; Calero K; Reed MF; Nsiah-Dosu S; Himes D; Kubo H; Kinsey CM; Majid A; Hogarth DK; Kaplan PV; Case AH; Makani SS; Chen TM; Delage A; Zgoda M; Shepherd RW
Ann Am Thorac Soc; 2024 Feb; 21(2):251-260. PubMed ID: 37948704
[No Abstract] [Full Text] [Related]
3. Bronchoscopic Lung Volume Reduction in Patients with Emphysema due to Alpha-1 Antitrypsin Deficiency.
Everaerts S; Hartman JE; Van Dijk M; Koster TD; Slebos DJ; Klooster K
Respiration; 2023; 102(2):134-142. PubMed ID: 36549279
[TBL] [Abstract][Full Text] [Related]
4. The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema.
Li S; Wang G; Wang C; Gao X; Jin F; Yang H; Han B; Zhou R; Chen C; Chen L; Bai C; Shen H; Herth FJF; Zhong N
Respiration; 2019; 97(5):416-427. PubMed ID: 30554211
[TBL] [Abstract][Full Text] [Related]
5. Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency.
Perotin JM; Leroy S; Marquette CH; Mal H; Dutau H; Bourdin A; Vergnon JM; Pison C; Barbe C; Deslee G;
Int J Chron Obstruct Pulmon Dis; 2018; 13():3645-3649. PubMed ID: 30464447
[TBL] [Abstract][Full Text] [Related]
6. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
7. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
8. Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial.
Dransfield MT; Garner JL; Bhatt SP; Slebos DJ; Klooster K; Sciurba FC; Shah PL; Marchetti NT; Sue RD; Wright S; Rivas-Perez H; Wiese TA; Wahidi MM; Goulart de Oliveira H; Armstrong B; Radhakrishnan S; Shargill NS; Criner GJ;
Ann Am Thorac Soc; 2020 Jul; 17(7):829-838. PubMed ID: 32223724
[No Abstract] [Full Text] [Related]
9. Efficacy of the Spiration Valve System in Patients with Severe Heterogeneous Emphysema: A Systematic Review and Meta-Analysis.
Majid A; Labarca G; Uribe JP; Kheir F; Pacheco C; Folch E; Jantz MA; Mehta HJ; Patel NM; Herth FJF; Fernandez-Bussy S
Respiration; 2020; 99(1):62-72. PubMed ID: 31760389
[TBL] [Abstract][Full Text] [Related]
10. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM).
Kemp SV; Slebos DJ; Kirk A; Kornaszewska M; Carron K; Ek L; Broman G; Hillerdal G; Mal H; Pison C; Briault A; Downer N; Darwiche K; Rao J; Hübner RH; Ruwwe-Glosenkamp C; Trosini-Desert V; Eberhardt R; Herth FJ; Derom E; Malfait T; Shah PL; Garner JL; Ten Hacken NH; Fallouh H; Leroy S; Marquette CH;
Am J Respir Crit Care Med; 2017 Dec; 196(12):1535-1543. PubMed ID: 28885054
[TBL] [Abstract][Full Text] [Related]
11. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
12. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial.
Criner GJ; Delage A; Voelker K; Hogarth DK; Majid A; Zgoda M; Lazarus DR; Casal R; Benzaquen SB; Holladay RC; Wellikoff A; Calero K; Rumbak MJ; Branca PR; Abu-Hijleh M; Mallea JM; Kalhan R; Sachdeva A; Kinsey CM; Lamb CR; Reed MF; Abouzgheib WB; Kaplan PV; Marrujo GX; Johnstone DW; Gasparri MG; Meade AA; Hergott CA; Reddy C; Mularski RA; Case AH; Makani SS; Shepherd RW; Chen B; Holt GE; Martel S
Am J Respir Crit Care Med; 2019 Dec; 200(11):1354-1362. PubMed ID: 31365298
[No Abstract] [Full Text] [Related]
13. Efficacy and Safety of the 9-mm Intrabronchial Valve in Patients with Advanced Emphysema.
Kontogianni K; Gompelmann D; Valipour A; Gerovasili V; Schuhmann M; Stanzel F; Herth FJF; Eberhardt R
Respiration; 2020; 99(4):333-343. PubMed ID: 32311695
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary
Lessard E; Young HM; Bhalla A; Pike D; Sheikh K; McCormack DG; Ouriadov A; Parraga G
Acad Radiol; 2017 Nov; 24(11):1402-1411. PubMed ID: 28645458
[TBL] [Abstract][Full Text] [Related]
15. Alpha
Foray N; Stone T; White P
Thorac Surg Clin; 2021 May; 31(2):139-160. PubMed ID: 33926668
[TBL] [Abstract][Full Text] [Related]
16. Maximal mid-expiratory flow detects early lung disease in α
Stockley JA; Ismail AM; Hughes SM; Edgar R; Stockley RA; Sapey E
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356373
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease.
Stoller JK; Aboussouan LS; Kanner RE; Wilson LA; Diaz P; Wise R;
Ann Am Thorac Soc; 2015 Dec; 12(12):1796-804. PubMed ID: 26653189
[TBL] [Abstract][Full Text] [Related]
18. Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial.
Eberhardt R; Slebos DJ; Herth FJF; Darwiche K; Wagner M; Ficker JH; Petermann C; Hübner RH; Stanzel F; Shargill NS; Valipour A;
Respiration; 2021; 100(12):1174-1185. PubMed ID: 34350884
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience.
Gauvain C; Mornex JF; Pison C; Cuvelier A; Balduyck M; Pujazon MC; Fournier M; AitIlalne B; Thabut G
COPD; 2015 May; 12 Suppl 1():46-51. PubMed ID: 25938292
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
